<DOC>
	<DOCNO>NCT00978458</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether radiation therapy effective give together without temozolomide treat patient low-grade glioma . PURPOSE : This randomized phase III trial study radiation therapy see well work give together without temozolomide treat patient low-grade glioma .</brief_summary>
	<brief_title>Radiation Therapy With Without Temozolomide Treating Patients With Low-Grade Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether addition temozolomide fractionate radiotherapy improves progression-free survival ( PFS ) patient symptomatic progressive low-grade glioma . - To determine whether addition temozolomide fractionate radiotherapy improves median overall survival ( OS ) patient . Secondary - To determine whether combination therapy temozolomide radiotherapy improve maintains cognition quality life compare radiotherapy alone . - To compare toxicity ( severe bad [ ≥ grade 3 ] ) radiotherapy v without temozolomide patient . - To assess impact presence absence 1p 19q deletion PFS OS . - To determine impact 1p 19q status PFS OS patient treat temozolomide . - To create tumor tissue bank , include plasma germ line DNA , within ECOG Pathology Coordinating Office . OUTLINE : This multicenter study . Patients stratify accord age ( &lt; 40 year vs ≥ 40 year ) , 1p 19q status ( delete vs either/both intact v undeterminable ) , pre-operative maximum tumor diameter ( &lt; 6 cm v ≥ 6 cm [ base T2 FLAIR MRI ] ) , Karnofsky performance status ( 60-70 % vs 80-100 % ) , contrast enhancement pre-treatment MRI scan ( present v absent ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo 3-dimensional conformal intensity-modulated radiotherapy daily 5 day week 5½ week ( 28 fraction ) . - Arm II : Patients undergo radiotherapy arm I receive concurrent oral temozolomide daily 5½ week . Beginning 28 day completion chemoradiotherapy , patient receive oral temozolomide alone daily day 1-5 . Treatment temozolomide repeat every 28 day 12 course absence disease progression unacceptable toxicity . Some patient undergo quality-of-life neurocognitive ( e.g. , visual scan speed , divide attention , language , memory , fine motor skill ) assessment baseline , annually disease progression , time disease progression . Tumor tissue sample collect baseline confirmation diagnosis determination 1p 19q deletion status . Peripheral blood , serum , additional tumor tissue sample may collect research study . After completion study treatment , patient follow periodically 15 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* supratentorial lowgrade glioma , include 1 following : Grade 2 astrocytoma Grade 2 oligodendroglioma Grade 2 oligoastrocytoma ( mixed glioma contain astrocytoma oligodendroglioma ) NOTE : *If pathology multiple procedure support diagnosis brain tumor , qualify pathology grade 2 astrocytoma , oligodendroglioma , oligoastrocytoma must recent pathological diagnosis ; pathological diagnosis grade 3 4 glioma time Paraffinembedded tumor specimen available submission confirmation pathological review determination 1p 19q deletion status Patients must currently meet ≥ 1 follow criteria* : Uncontrolled symptom , define follow : Headaches associate mass effect Uncontrolled seizure despite two different antiepileptic drug regimen ( i.e. , two antiepileptic drug test either sequentially combination ) Focal neurological symptom Cognitive symptom deficit Tumor progression serial MRIs , define follow : New progressive enhancement New progressive T2 FLAIR signal abnormality Age ≥ 40 year NOTE : *Patients &lt; 40 year age whose symptom lowgrade glioma seizure wellcontrolled antiepileptic drug AND evidence radiographic progression eligible . Patients undergone gross total resection detectable residual disease eligible No pilocytic astrocytoma , ganglioglioma , pleomorphic xanthoastrocytoma , dysembryoplastic neuroepithelial tumor PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % WBC ≥ 3,000/mm^3 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hematocrit ≥ 30 % Bilirubin ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN Creatinine ≤ 2.0 time ULN Not pregnant nursing Negative pregnancy test Able undergo MRI without contrast No malignancy within past 5 year , except nonmelanoma skin cancer cervical carcinoma situ No uncontrolled infection No known HIV positivity No medical disorder would increase risk associated radiotherapy temozolomide No disorder would limit life expectancy &lt; 5 year PRIOR CONCURRENT THERAPY : No prior radiotherapy , cytotoxic chemotherapy , radiosurgery , investigational therapy direct brain tumor Any number prior surgical procedure brain tumor allow No prior radiotherapy head unless radiotherapy port entirely exclude brain At least 2 week since prior brain surgery ( e.g. , stereotatic biopsy , open biopsy , resection ) At least 6 week since prior MRI chest xray If resection perform , MRI surgery require</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>